Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: August 30, 2005
Last updated: November 21, 2008
Last verified: November 2008
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2007
  Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)